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Abstract
The proposed layered and component based
software architectural style enables data sharing and
accessibility of computational software components
across Biomedical Science problem domains. It also
opens the door to translational informatics, which
bridges the gap between knowledge, generated in
biomedical science, and clinical practices. Software
applications created from the proposed software
architectural style, are able to support continuous drug
repurposing. They exploit the semantic, which exists,
and is available across biomedical problem domains,
between drug chemical compounds, their biological
targets, particularly unintentional targets and drug
therapeutic effects. The excerpt from the proposed
software architecture has already been deployed in a
computationally light-weight software application,
which manages drug repurposing through reasoning
upon the available semantic. However a full scale
implementation and full deployment of the software
architecture, plus data sharing across the spectrum of
biomedical research and disciplines, would require
some changes in the way therapeutic drugs are
discovered, tested and approved.

1. Introduction
Drug repurposing has been in the focus of drug
development research for almost 2 decades [1] and it is
recognized as an important part of new drug
development processes with significant business,
technical and scientific challenges and strategies [2].
Reinvestigations of existing, i.e. approved drugs, from
various perspectives, including academic, existed in the
literature almost 10 years ago [3,4], and drug-disease
relationships, for discovering novel uses of drugs [5]
have been exploited for triggering research on
computational drug repositioning [6] and its prediction
in complex diseases [7]. It is interesting that almost 10
years ago a database for network-based drug
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repositioning was developed and in 2013 an initiative to
start open source approaches for the repurposing of
existing and failed candidate drugs was proposed in [9].
At the same time we had one of the first attempts to use
machine learning for drug repurposing [10], and shortly
afterwards interest in applying drug repositioning for
discovering cancer drugs took off [11,12]. In the last 5
years, a variety of publications, which address new
challenges in drug repurposing, started appearing [13].
Some of them paid attention to the barriers in the
process of drug discoveries, such as clinical trials, where
their costs may adversely affect drug development [14].
Updated and modernized aspects of drug repositioning
were urgently needed [15,16,17] and in the last 2 years
we find publications in which trends, resources,
repositioning approaches and challenges have been
debated again [18-21]. Computational drug repurposing
has started [22], their validation strategies have been
reviewed [23] and finally there is an initiative to look at
various tools which could accelerate the drug discovery
process [24,25]. In this year, 2020, we still find new
publications which talk about challenges and
opportunities with drug repurposing [26,27], but the
appearance of the covid-19 pandemic, brought into
daylight all existing ideas on drug repurposing, aiming
to answer the demand for finding treatment for
coronavirus [28-33].
This rather long introduction to the world of drug
repurposing indicates that we have two problems here.
a) However we wish to believe that experimental and
computational methods, for supporting drug
repositioning, have been defined and exercised in
the last 2 decades, obviously there is no universal
and known computational method for supporting
the process and there is no comprehensive drug
repositioning strategy.
b) The process of drug discoveries and repositioning
is far from being trivial, but it is likely that it faces
similar obstacles found in translational informatics
[34-36].
Scientific discoveries, data, and
information, available from experiments and
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research in biomedical science do not necessarily
reach many sub-disciplines across biomedicine,
pharmaceutical science and clinical practice.
Sharing of data and scientific discoveries is
essential for the journey forward and there is no
evidence that it is happening at present (in 2020).
It is very difficult to address a) and b) above.
However, there is something interesting discovered
in all these publications from 2004 onwards.
Computer scientists are rarely found in the teams
who have led research on drug repurposing. Any
novel solution in drug repurposing would have
some kind of computations at its core, and would
require the expertise of computer scientists to
guarantee generic and deployable solutions. This
means that now, in 2020, when software
technologies
and
modern
computational
environments have penetrated almost every aspect
of our lives, it would be unreasonable to keep
computer science away from research tables and
debates on unresolved challenges we still have in
drug repurposing. The issue of data sharing, as
described in b) above can be addressed and resolved
from computer science and software engineering
perspectives and consequently, if we exercise a
small shift in thinking, we might be in a position to
influence existing or find new pathways towards
research solutions for problems described in a).
The authors’ interest in drug repurposing,
translational informatics and knowledge sharing in
biomedicine is not new [37,38,39]. However, the
research was mainly focused on computational models
which could bring solutions to problems in biomedical
informatics, through the manipulation of semantics
stored in such environments. What is currently needed
is to collate all proposed computations into a conceptual
software architectural model, which can show exactly
how information and data are possible to share in the
biomedical field and relevant computations built across
shared data. These conceptual software architectures
are applicable in many biomedical problem domains
[40] and it is just a small step forward to apply them in
drug repositioning.
This paper proposes a generic, layered and
component based software architectural style [41,42]
for creating software applications which could initiate
addressing a) and b) above. However, the most
important role of the software architecture (SA) is to
focus on sharing of data and knowledge across wider
problem domains in biomedicine and pharmacology,
and reusing existing computational models, with their
data repositories for enabling more efficient discoveries
of data for drug repurposing. A working prototype from
[43] proves that there are still opportunities to create
new computations, which would find a way towards

drug repurposing. This is particularly true if we employ
software technologies which could interpret the
meaning of biomedical data in data-sharing, and secure
reasoning upon its semantic, for the purpose of finding
relevant semantic in data which could take us toward
drug repurposing.
Therefore Semantic Web
Technologies (SWT) [44,45] and their languages, OWL
and SWRL [46,47] could still be used for retrieving
existing knowledge in formal medical and biomedical
ontologies. The SWT can also be used for reasoning
upon SWRL enabled OWL ontologies, in order to create
new computations which would be specific for drug
repurposing, as illustrated in [43].
Finally, the proposed SA should not be interpreted
as another attempt to create a new platform or
framework under which we can create a miracle solution
for drug repurposing. It should be the opposite: a new
light-weight software application, built according to the
architectural style, easily deployable and not creating
enormous computational burdens on anyone who
wishes to run such computations. Obviously, the issue
of data sharing is essential and could trigger further
thinking in the manipulation of data from different
sources or created by different parties, which might not
be directly involved in drug repurposing. However,
these are the questions which could be answered by
corporations and laboratories which generate
biomedical data and would depend on their readiness to
contribute towards achieving a joint goal by sharing
them. Consequently, this research can not answer such
questions, but could prove that the proposed SA is
feasible, and can be deployed if data sharing culture is
in place.
The paper is organized as follows. Section 2
overviews related work in which we look at specific
computational solutions, using the SWT for drugrepurposing. Section 3 elaborates on the proposed SA
for addressing the problem and in Section 4 we illustrate
the proposal and in section 5 give a generic ontological
model which would infer drug repositioning according
to the semantic relationships between drugs and their
(un)intended targets. We conclude in section 6.

2. Related Work
At the time of writing the paper there were no
publications which propose a software architectural
model for long term solutions in drug repurposing,
which would include data sharing and reusability of
existing computations. In this section, a review of
papers which come close to the excerpts from this
proposal are outlined. Attention is also paid to
computational solutions, which use reasoning, SWT and
formal ontologies to aid the drug repurposing process.
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There is one publication, which helps in promoting
the feasibility of our proposal and, at the same time,
influences the implementation of the prototype from
[43]. The idea of exploiting the drug-target
identification, using side-effect similarity, as described
in [48], may have an impact on the process of
discovering new purposes of existing drugs. It enables
focusing on phenotypic side-effect similarities in order
to infer if two drugs share the same target. The power
of side effects could add more semantics to any OWL
model used for knowledge presentation and strengthen
the reasoning process needed in drug re-positioning.
However, this is not the only way of reasoning/inference
for drug repositioning, but it remains a powerful
mechanism for computational analysis of the semantic
of drugs and their unintentional biological targets. If
these ideas could be fully converted into a
computational model as in [43] then there is an
opportunity to find more overlapping semantic between
drugs and their intended and non-intended biological
targets.
A new wave of innovations, which use SWT tools
for drug discoveries from [49] would fit within the main
structure of the proposed SA model. However, none of
the papers referenced in [49] come close to the proposed
SWRL enabled OWL model from [43] for one
important reason. Our proposal includes building a
software engineering solution with a software
application in mind, and creating a computational model
based on SWRL enabled reasoning. This is rather
different to the traditional use of ontologies for semantic
annotations in drug discoveries.
The deployment of learning and mining
technologies for drug re-positioning was initiated in this
decade [50,10, 7] because of an excessive amount of
data and information we have been generating in
Biomedical science and research. Consequently, we
talk about databases for network based drug
repositioning [8], the changed landscape of academic
drug discoveries [15] and pathway analysis based on
Public Database mining as in [13], as mentioned in the
introduction. However, this we should not pursue a
uniform computational model for this problem domain.
It is sufficient that all current results of biomedical
research, including predicting drug side effects from
Drug – Target relationships as in explained [51] and
relating proteins to drug side effects as described in [52],
and finding their space in computational models from
the proposed SA, which was emphasized in [43]. It goes
without saying that work from [53-55] would find its
space in the proposed SA model.
It was mentioned in the Introduction that a very
rich, published literature, focusing on drug
repositioning, has been sourced from papers which do
not involve enough (if any?) computer scientists.

Therefore all their work remains in the field of
knowledge building and classifications. This is far away
from any universal and long term solutions which could
enable a constant process of drug repositioning.
Hopefully, this proposal might change the picture of the
this problem domain landscape.

3. The Proposal: SA Model
The proposed SA model is in Figure 1. As a layered
and component based architectural style it has specific
characteristics which resemble the MVC pattern, typical
for software modelling, where separation of concerns is
essential. For readers not familiar with principles of
software architectures and patterns, it is important to pay
attention to layering of software components which
secure the separation of user interfaces, computational
components and software components which house data
and data repositories, in general. Therefore each layer of
the SA model in Figure 1 contains software components
of the same type.

Figure 1: The Proposed Software Architecture for FRD
(Finding Repurposed Drug)

The computational layer is very important because
it can house a variety of computational models and thus
the SA ensures that these computations are fed by
relevant data repositories. Very often in computational
components we recognize a variety of functionalities
which are supposed to be delivered by software
applications generated from the SA. Therefore the Data
layer must contain all possible data repositories which
might be needed by any of the computational
components from the middle layer.
One of the most important aspects of software
component layering is that its deployment is managed
by Integrated Development Environments (IDE) and
thus these tools secure communication between layers.
Also the proposal strictly follows an architectural style
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which allows communication between software
components by utilizing the role of each layer. The
separation of concerns allows adding more software
components in each layer if needed. Therefore more
computations are welcome, as long as we have data
repositories available for running such computations.
Distribution of these software components is feasible
and thus they may not in reality always belong to the
same software applications. In other words data
repositories may be shared across various computations
as long as there is agreement between different parties,
who are the owners of these data repositions that data
could be shared.
In summary, data sharing across computations is
not feasible i) if the rules of software component
layering are not followed and ii) if we do not keep
separation of concerns in mind. Bearing in mind that
today, we often compute with data which do not
originate in our computational environment, then it is of
the upmost importance that the SA defines which
computations will be dependent on which data
repository(ies).

3.1. Description of Computational Software
Components
The SA from Figure 1 is generic, but software
components within it are technology specific. When
defining and proposing any SA style, we must ensure
that it is deployable within an IDE. In this particular
case, NetBeans IDE and J2E technology are used for the
deployment of the proposal and components carry
technology specific tags. Therefore the computational
components in Figure 1 are deployed as either servlets,
or java beans, which in turn means that we can include
Java level of programming, SQL types of code together
with potential database definitions and retrievals plus
any other type of computing we may need, within the
middle layer of Figure 1. OWL-API is a software
component which contains an API in order to take us
towards software components deployed with different
technologies: SWT and its languages. In these cases,
computations within SWRL enabled OWL ontologies
happen with a rule language, which performs reasoning
upon data stored in OWL concepts. This means that
reasoning is performed using an unusual, but often used
data repository denoted in Figure 1 as green and yellow
circles (left and rightmost parts of the data layer in
Figure 1). SWT is a different technology compared to
our traditional database management and programming
with procedural languages and thus this computational
part has 2 pathways: either retrieval of data through
OWL-API using SPARQL or reasoning upon data using
SWRL. Obviously data stored in OWL ontologies could
be accessed through OWL-API only, but these plug-ins

are available across many IDE and work very well
within Android operating environments. In summary, a
green bidirectional arrow denotes initiation of SPARQL
retrievals or reasoning with SWRL, plus any other type
of defining essential OWL concepts or defining SWRL
rules in advance. The yellow bidirectional arrow means
that the model supports retrievals with SPARQL and
definition of OWL classes and their semantics. A onedirectional yellow arrow supports SPARQL retrievals
only. Blue arrows refer to database definitions,
retrievals and updates.
Red arrows denote access to unstructured data and
data sets, often used for processing big data and running
various types of predictions, such as machine learning
classifications (to mention just the most popular way of
performing predictive inference in modern computing).
These software components, reserved for ML
algorithms, are tagged as servlets, but they could have
their own API which could take the computations
towards software tools to run predictions upon available
data sets. This part of the SA model open doors to
running predictions with ML algorithms, together with
SQL retrievals from traditional transactional processing
and reasoning upon OWL concepts, all under one
umbrella of software applications which uses a variety
of software technologies.

3.2. Description of Functionalities Defined in
the SA
Figure 1 introduces three different types of
functionalities. They are visible through its vertical
lines, which cross the layers of the SA.
On the right part of the figure, we define FRD
which stands for Finding Repositioning for a Drug. A
possible reposition is a result of reasoning upon SWRL
enabled OWL ontology, denoted in the green circle
which is a software component containing OWL
concepts and reasoning rules associated to them.
However the reasoning depends on the OWL model, and
the OWL model in turn depends on the knowledge
extracted from Biomedical data repositories. They can
range from formal ontologies (the left bottom part of the
SA) and various unstructured (e.g. data sets) and
structured repositories available across biomedical
research. Therefore, Figure 1 signals that we have to
have a structured repository for defining drug
repurposing criteria, which can be generated for a
particular drug after retrieving the existing formalized
knowledge and data from biomedical experiments. The
SQL retrievals through FRD java class brings semantics
for creating ontological concepts and reasoning rules in
FRD computational ontologies.
The middle part of Figure 1 accommodates the
functionality of Defining Repurposing Criteria (DRC).
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This computation is likely to operate in SQL like
environments where various database retrievals from
biomedicine could bring enough knowledge to define
criteria. The data component of this functionality is
represented by only one database symbol, but in reality,
there should be numerous structured repositories which
can contain semantic relevant for defining the criteria.
Whether these repositories should belong to the middle
functional column (DRC) or to the left one, could be
debated, but the layered SA could accommodate any
changes we may have when associating computations
from the middle layer with data repositories.
The left part of Figure 1 is likely to be found outside
the software applications which exactly compute drug
repositioning (right part of Figure 1). This means that
the world of biomedical knowledge is responsible for
creating and storing their knowledge. It may contain its
own computations in order to process biomedical data
as part of their own research; it may run ML algorithms
for the purpose of running biomedical experiments and
research and may create formal ontologies (yellow oval
symbol) for accumulating biomedical knowledge.
DUBS stands for Defining and Updating Biomedical
Sources, and thus it is likely that the DUBS.Sservelet
will operate outside the environment where FRD
computes. However, their “connection” is in sharing of
data (possibilities are a yellow one-directional line and
red arrows).

This was easy to collect and use as our repurposing
criteria, because some of the publications available
online do follow predication semantics [56, 57] in which
relationships between drugs and their targets can be
presented as the subject-predicate-object triples
[58,59]. Considering that OWL concepts are based on
RDF triples and they do support semantically subjectpredicate-object notion, it was extremely easy to create
OWL concepts, find their constraints and write SWRL
rules for the example above.

Figure 2 Excerpts from the Implementation

4. Illustration of the Proposed SA
Figure 2 denotes which part of the proposed SA was
deployed and which data repositories we used in the
deployment, for creating a software application. The
software application is circled with a green broken line.
The FRD Servlet and Java classes were
programmed, but we did not have the Repurposing
Criteria Data repository explicitly available and thus had
to create it. The deployment of the FRD functionality
has been published in [43] with ontological concept and
reasoning upon them. Figures 3 and 4 show its OWL
model and the reasoning process, both taken from [43].
The most important part was the repurposing criteria,
which was deployed as OWL constraints but extracted
from the literature, i.e. published papers because there is
no formal source which stores semantics relevant to
drug repurposing.
On this occasion, we looked at side effects of drugs
approved for a specific target (gene, biological
manifestation) and reason upon the semantic
overlapping between
Disease-drug-approved target-side effectsdrug unintentional target-disease

Fig. 3 Ontological Classes for DRUG Ontology [43]

The reasoning rules have “found” that
“Amantadine could be repositioned for Parkinson’s
disease”.
It is important to note that the implemented model
and reasoning from [43] proved the concept: we could
infer drug repositioning through reasoning. However,
our criteria for repurposing is one of many possibilities
to represent a complex relationship between drugs and
their biological targets, which can be formalized though
OWL concepts and used in reasoning.
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5. Formal Ontological Model for FRD
Computations
The OWL model from Figure 3, is repurposing
criteria specific in terms of using side effects for finding
possibilities of drug repurposing. However, this paper
offers a generic OWL model, for any other type of
repurposing criteria. For example, it could use semantic
relationship between drugs intentional and noninternational targets. Figure 5 shows a generic OWL
model with the reasoning processes interwoven. This is
probably one of many possibilities of using description
logic in managing overlapping semantics between OWL
terms for drug repurposing, and thus more debate is
needed to find out which repurposing criteria could be
seen as the most generic.

implementation in [43], where its inference is in the
form of the object properties. This means that the
individual of Di class (a particular DRUG) has been
repurposed to be relevant for Diseases. Therefore the
power of the model is in our way of describing drugs
through their targets. Targets, from the computer
science point of view, can really be ANYTHING which
contains the semantic relevant to the drug and thus the
model also allow predicate semantic to be used as much
as possible and pay more attention to un-intentional
targets, which may hide drug effects not visible, or
known or even not reported. For readers interesting in
the applicability of generic OWL models, as in Figure 5
in computational reasoning, when OWL model and
SWRL reasoning become a core part of the main
computational model, we suggest reading the authors’
earlier publications.

Figure 4: The Reasoning Process for Inferring Drug
Repurposing (with OWL Classes and Constraints) [43]

The generic OWL model with the reasoning
process in Figure 5 is self-explanatory. Drug Drdugi is
described through its intentional {ti,1, ti,2,, … ti,n} and
unintentional targets: {ti,n+1, ti,n+2,, … ti,m}, and the same
applies to drug Drugj with {tj,1, tj,2,, … tj,k}, and {tj,k+1,
tj,k+2,, … tj,l.} where i,j are elements of N. The most
powerful part of the model is very difficult to draw and
requires a detailed table with object properties defined
between the domain and range classes, but the bidirectional black arrow between Drugi and Drugj
classes is the place where we define object properties on
the diagram. They may contain all possible semantic,
including the overlapping semantic between Drugi and
Drugj, plus the set of targets: {ti,1, ti,2,, … ti,n}, {ti,n+1,
ti,n+2,, … ti,m},}, {tj,1, tj,2,, … tj,k}} {tj,k+1, tj,k+2,, … tj,l., }.
What is important to read from the diagram is that the
result of reasoning is not a particular new drug: it is an
object property between existing drug Dj and Diseasei,
which did not exist before (red arrow shows where the
reasoning happens and what is being inferred). From
this perspective, the model does not depart from the

Figure 5: Generic OWL Model for continues Drug
Repurposing

6. Conclusions
This paper touches the tip of the iceberg of the
problems we face in the field of sharing and
disseminating data and knowledge across Biomedical
science and related disciplines [59] and the issue of drug
repositioning is not an exception. Since the early 2000s
we have not conquered the drug repositioning problem,
in spite of reading some very interesting proposals and
ideas. To the eyes of computer scientists, the lack of
their involvement in the problem solving process is a
problem. Also, the absence of a generic SA model which
must allow data sharing across disciplines which should
enable sharing of data and knowledge, can not take us
forward in drug repositioning. The proposal shows how
feasible and efficient some software solutions in this
field could be. The issues of heterogeneity and
interoperability in this field, privacy of medical data and
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data in general are very easy to resolve and the model
we propose, together with its separation of concern can
guarantee almost all of them. These types of SA have
been around for almost 2 decades and are probably one
of the most successful ways of constructing software in
modern computing.
This work would be primarily of interest to
pharmaceuticals and research in new drug development.
However, there is something else here which should
attract the attention of any lab and research group in
Biomedical Science or Pharmacology. Their research
results sometimes remain completely buried in peerreviewed publications, which are being generated at
enormous speed, as we write this. It has become
impossible to have any overall picture of research
progress in Biomedical science and interesting details of
research results sometimes never get read or evaluated.
There should be a joint interest in sharing data and
information across all these disciplines through software
applications and the message from computer scientists
is that this is very feasible and not difficult to design and
implement.
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